AstraZeneca announced the positive results of the NIAGARA phase III clinical trial on June 25th local time. The analysis shows that compared with front-line treatment, the heavyweight immune therapy Imfinzi combined with chemotherapy can significantly prolong the overall survival (OS) of muscle-invasive bladder cancer (MIBC) patients in statistical and clinical aspects. The press release stated that this is the first immune therapy scheme that can extend the survival of bladder cancer patients before and after surgery.
阿斯利康膀胱癌新疗法Imfinzi取得3期试验积极结果
AstraZeneca's new bladder cancer therapy, Imfinzi, has obtained positive results in Phase III trials.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.